News Summary
PositiveArm delivered record Q4 FY2026 revenue of $1.49B with strong 29% licensing growth and 11% royalty growth, driven by robust AI/data center demand. However, Morgan Stanley's downgrade in July 2026 flagged weakened near-term setup despite long-term AI chipmaking potential, and the failed Cerebras acquisition attempt suggests execution risks in Arm's strategic pivot to direct chip manufacturing.
Red flags
- •Morgan Stanley downgrade to Hold citing weakened near-term setup for AI chipmaking transition
- •Failed Cerebras acquisition attempt signals potential difficulty executing on AI chip strategy
- •CEO dual role at SoftBank and Arm creates potential distraction and conflict of interest concerns
Funds Reducing / Exiting (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | 28K | -78,594 | $10M | 0.6% | -74% | Existing |
| Whale Rock Capital | Alex Sacerdote | 0 | −452K | — | 0.9% | -100% | EXITED |
| Point72 | Steve Cohen | 0 | −14K | — | <0.1% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 3 | 1.98 | -18.6% |
| Q1 2026 | LONG | 3 | 4.03 | +65.0% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.